Cytokine Expression in Psoriasis Patients With and Without Joint Involvement

Study Overview
=================
Brief Summary
-----------------
The objective of the resarch is to study the cytokine profile of patients with psoriatic arthritis and psoriasis in order to better understand the pathophysiology of the disease and the contribution of cytokines to the presence or absence of joint involvement. This research will compare cytokines levels in sera, in PBMC culture after LPS or CD3/CD28 agonist antibodies, and in skin biopsy.

Detailed Description
-----------------
Psoriatic arthritis and Cutaneous Psoriasis are polygenic inflammatory disorders with high burden on the quality of life of patients. Pathophysiology of those disease remain incompletely understood. Recent publications seem to demonstrate an implication of IL-1 family cytokines in the pathogenesis of both diseases. In the literature, results are discordant and focus mainly on cytokines levels in serum of patients. Moreover, few studies compare psoriatic arthritis patients with cutaneous psoriasis patients. We propose here to study cytokines profiles of patients with those conditions in sera, after ex-vivo stimulation of peripheral blood mononuclear cells, and in skin biopsies.

Official Title
-----------------
Cytokine Expression in Sera, ex Vivo Stimulated Peripheral Blood Mononuclear Cells Culture, and Skin in Psoriasis - Comparison of Patients With and Without Joint Involvement

Conditions
-----------------
Psoriasis, Psoriatic Arthritis

Intervention / Treatment
-----------------
* Other: Blood sample collection
* Other: Skin sample collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: For psoriasis patients : Age over 18 years old Signed informed consent 5 year old psoriasis at least At least one skin lesion over 2 cm Without any articular symptoms Without any DMARDs Without anticoagulant treatments or coagulation disease With normal articular and enthesis sonography For psoriatic arthritis patients : Age over 18 years old Signed informed consent Psoriatic arthritis according to CASPAR criteria Without any DMARDs Without anticoagulant treatments or coagulation disease With at least one synovitis at inclusion For controls Age and sex matched with a patient without any rheumatic or dermatologic medical conditions No treatment with corticosteroïds or non-steroïdial anti-inflammatory drugsAge over 18 years old Exclusion criteria: ▪ For psoriasis patients : Joint damage according to CASPAR criteria Echography activity in favor of chronic inflammatory rheumatism For patients and controls: Without social protection rights People under judiciary protection, of less than 18 years old, pregnant woman, breast feeding women, jailed patients.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Psoriasis<br> | Other: Blood sample collection<br>* Blood sample collection<br>Other: Skin sample collection<br>* Skin sample collection<br>|
| Experimental: Psoriatic arthritis<br> | Other: Blood sample collection<br>* Blood sample collection<br>Other: Skin sample collection<br>* Skin sample collection<br>|
| Active Comparator: Controls<br> | Other: Blood sample collection<br>* Blood sample collection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of cytokine levels in sera, after culture of PBMC stimulated with LPS or CD3/CD28 agonist antibodies between the three groups | Comparison of cytokine levels in sera, after culture of PBMC stimulated with LPS or CD3/CD28 agonist antibodies between the three groups | At inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of cytokine levels in skin biopsies between Psoriatic Arthritis and Cutaneous Psoriasis patients | Comparison of cytokine levels in skin biopsies between Psoriatic Arthritis and Cutaneous Psoriasis patients | At inclusion | 
| Correlation of cytokine levels with rheumatologic disease activity, or dermatologic disease activity | Correlation of cytokine levels with rheumatologic disease activity, or dermatologic disease activity | At inclusion |